Tenon Medical to Release 2025 Financial Results on March 19, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy TNON?
Source: PRnewswire
Tenon Medical Inc. saw a significant price increase of 20.93% in pre-market trading as it crossed above its 5-day SMA.
The company announced that its fourth quarter 2025 revenue is projected to be between $1.45 million and $1.48 million, indicating approximately 90% year-over-year growth. Additionally, full year 2025 revenue is expected to range from $3.91 million to $3.94 million, reflecting a year-over-year growth of about 20%. This strong financial outlook, along with the upcoming earnings release scheduled for March 19, 2026, has contributed to positive investor sentiment.
This anticipated financial performance highlights Tenon Medical's robust development and increasing market demand in the medical device sector, particularly following the launch of the Catamaran SI Joint Fusion System.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNON
Wall Street analysts forecast TNON stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.835
Low
2.50
Averages
2.75
High
3.00
Current: 0.835
Low
2.50
Averages
2.75
High
3.00
About TNON
Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tenon Medical Q4 Earnings Exceed Expectations
- Earnings Highlights: Tenon Medical reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.07, indicating a positive trend in the company's profitability improvement.
- Revenue Surge: The company achieved $1.5 million in revenue for Q4, representing an 87.5% year-over-year increase, which not only reflects strong market demand recovery but also highlights the company's success in product sales and market expansion.
- Outperformance: Revenue exceeded market expectations by $120,000, demonstrating Tenon Medical's strong adaptability and growth potential in the competitive medical device industry.
- Future Outlook: With ongoing optimization of its product line and market strategies, the company is expected to further drive revenue growth and improve profitability, thereby enhancing investor confidence.
See More
Tenon Medical Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Tenon Medical achieved a full-year revenue of $3.9 million in 2025, marking a 20% increase compared to 2024, with fourth-quarter revenue reaching $1.5 million, a remarkable 92% growth driven by increased surgical procedures and new physician users.
- Improved Gross Margin: The company reported a gross profit of $1 million in Q4 2025, representing 69% of revenue, a substantial increase from 46% in Q4 2024, indicating progress in cost control and sales efficiency.
- Enhanced Financial Flexibility: Tenon Medical successfully completed a $2.85 million At-The-Market PIPE financing and a $4.3 million private placement of senior convertible notes, providing the financial flexibility necessary for expansion and product rollouts, laying a solid foundation for future growth.
- Net Loss Improvement: Although the company reported a net loss of $12.6 million for the full year 2025, this reflects an improvement from a $13.7 million loss in 2024, demonstrating the company's efforts and effectiveness in controlling losses.
See More
Tenon Medical (TNON) Q4 2025 Earnings Transcript
See More
Tenon Medical Reports Record Q4 2025 Revenue Growth and Strategic Developments
- Record Revenue Growth: Tenon Medical achieved a full-year revenue of $3.9 million in 2025, marking a 20% increase, with Q4 revenue reaching $1.5 million, a 92% rise year-over-year, indicating significant growth driven by increased surgical procedures across the Catamaran and SImmetry+ platforms.
- FDA 510(k) Clearance Milestone: The company received FDA 510(k) clearance for the next-generation SImmetry+ SI-Joint Fusion System, expanding its portfolio to include a complementary lateral approach alongside Catamaran, which is expected to drive future market demand and revenue growth.
- Financing and Investment Plans: Tenon completed a $2.85 million At-The-Market PIPE financing and a $4.3 million private placement of senior convertible notes, with proceeds aimed at funding commercial expansion, product launches, and clinical studies, ensuring the company’s ongoing growth and innovation capabilities.
- Gross Margin Improvement: The gross profit for Q4 was $1 million, representing 69% of revenue, a significant increase from 46% in the prior year, reflecting the company's success in cost control and operational efficiency, which is expected to lay the foundation for sustainable growth in 2026.
See More
WALLACHBETH CAPITAL COMPLETES PRIVATE PLACEMENT OF SENIOR ORIGINAL ISSUE DISCOUNT CONVERTIBLE NOTES FOR TENON MEDICAL, INC, RAISING $4.3 MILLION IN GROSS PROCEEDS
Announcement of Closing: WallachBeth Capital has announced the closing of a private placement for senior original issue discount convertible notes.
Financial Details: The offering raised gross proceeds of $4.3 million.
See More
STMicroelectronics Shares Rise 4.3% in Pre-Market Trading
- Stock Performance: STMicroelectronics shares rose 4.3% in pre-market trading to $31.13, indicating optimistic market sentiment regarding the company's future performance, which may attract more investor interest.
- Market Dynamics: The upward trend in STMicroelectronics' stock could influence the performance of other related tech stocks, particularly in the semiconductor sector, further boosting investor confidence in the industry.
- Investor Sentiment: As the stock price increases, investor sentiment may become more positive, leading to increased capital inflow and enhancing the company's market position.
- Future Outlook: The rise in STMicroelectronics' stock price may signal positive developments in the company's technological innovation and market demand, further solidifying its competitiveness in the global semiconductor market.
See More
Tenon Medical Q4 Earnings Exceed Expectations
- Earnings Highlights: Tenon Medical reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.07, indicating a positive trend in the company's profitability improvement.
- Revenue Surge: The company achieved $1.5 million in revenue for Q4, representing an 87.5% year-over-year increase, which not only reflects strong market demand recovery but also highlights the company's success in product sales and market expansion.
- Outperformance: Revenue exceeded market expectations by $120,000, demonstrating Tenon Medical's strong adaptability and growth potential in the competitive medical device industry.
- Future Outlook: With ongoing optimization of its product line and market strategies, the company is expected to further drive revenue growth and improve profitability, thereby enhancing investor confidence.
See More
Tenon Medical Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Tenon Medical achieved a full-year revenue of $3.9 million in 2025, marking a 20% increase compared to 2024, with fourth-quarter revenue reaching $1.5 million, a remarkable 92% growth driven by increased surgical procedures and new physician users.
- Improved Gross Margin: The company reported a gross profit of $1 million in Q4 2025, representing 69% of revenue, a substantial increase from 46% in Q4 2024, indicating progress in cost control and sales efficiency.
- Enhanced Financial Flexibility: Tenon Medical successfully completed a $2.85 million At-The-Market PIPE financing and a $4.3 million private placement of senior convertible notes, providing the financial flexibility necessary for expansion and product rollouts, laying a solid foundation for future growth.
- Net Loss Improvement: Although the company reported a net loss of $12.6 million for the full year 2025, this reflects an improvement from a $13.7 million loss in 2024, demonstrating the company's efforts and effectiveness in controlling losses.
See More
Tenon Medical (TNON) Q4 2025 Earnings Transcript
See More
Tenon Medical Reports Record Q4 2025 Revenue Growth and Strategic Developments
- Record Revenue Growth: Tenon Medical achieved a full-year revenue of $3.9 million in 2025, marking a 20% increase, with Q4 revenue reaching $1.5 million, a 92% rise year-over-year, indicating significant growth driven by increased surgical procedures across the Catamaran and SImmetry+ platforms.
- FDA 510(k) Clearance Milestone: The company received FDA 510(k) clearance for the next-generation SImmetry+ SI-Joint Fusion System, expanding its portfolio to include a complementary lateral approach alongside Catamaran, which is expected to drive future market demand and revenue growth.
- Financing and Investment Plans: Tenon completed a $2.85 million At-The-Market PIPE financing and a $4.3 million private placement of senior convertible notes, with proceeds aimed at funding commercial expansion, product launches, and clinical studies, ensuring the company’s ongoing growth and innovation capabilities.
- Gross Margin Improvement: The gross profit for Q4 was $1 million, representing 69% of revenue, a significant increase from 46% in the prior year, reflecting the company's success in cost control and operational efficiency, which is expected to lay the foundation for sustainable growth in 2026.
See More
WALLACHBETH CAPITAL COMPLETES PRIVATE PLACEMENT OF SENIOR ORIGINAL ISSUE DISCOUNT CONVERTIBLE NOTES FOR TENON MEDICAL, INC, RAISING $4.3 MILLION IN GROSS PROCEEDS
Announcement of Closing: WallachBeth Capital has announced the closing of a private placement for senior original issue discount convertible notes.
Financial Details: The offering raised gross proceeds of $4.3 million.
See More
STMicroelectronics Shares Rise 4.3% in Pre-Market Trading
- Stock Performance: STMicroelectronics shares rose 4.3% in pre-market trading to $31.13, indicating optimistic market sentiment regarding the company's future performance, which may attract more investor interest.
- Market Dynamics: The upward trend in STMicroelectronics' stock could influence the performance of other related tech stocks, particularly in the semiconductor sector, further boosting investor confidence in the industry.
- Investor Sentiment: As the stock price increases, investor sentiment may become more positive, leading to increased capital inflow and enhancing the company's market position.
- Future Outlook: The rise in STMicroelectronics' stock price may signal positive developments in the company's technological innovation and market demand, further solidifying its competitiveness in the global semiconductor market.
See More
